PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer PFE will report its second-quarter 2025 earnings on Aug. 5, before market open. The Zacks Consensus Estimate for sales ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Bristol-Myers Squibb Company beats revenue forecasts & raises 2025 guidance. Click for key BMY catalysts, risks, and outlook ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, ...